Press Releases NanoViricides, Inc.

Equities

NNVC

US6300873022

Market Closed - Nyse Other stock markets 04:00:00 2024-05-01 pm EDT			5-day change	1st Jan Change
1.13 ^USD	-5.83%		-1.74%	+10.78%

Apr. 30	NanoViricides, Inc. Reports That the Phase I NV-387 Clinical Trial Is Completed Successfully and Data Lock Is Expected Soon	CI
Feb. 14	NanoViricides, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon	07:29am	AQ
NanoViricides: Fiscal Q2 Earnings Snapshot	Feb. 14	AQ
Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications beyond COVID Treatment, Explains NanoViricides, NV-387 Could be As Revolutionary as Antibiotics	Feb. 02	AQ
Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides	Jan. 30	AQ
NanoViricides updates progress on Phase 1a/1b clinical trial of antiviral drug candidate NV-387	Nov. 29	AQ
NanoViricides Has Filed its Quarterly Report, NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications	Nov. 16	AQ
NanoViricides, Inc. - Broad-Spectrum Antiviral NV-387 in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development	Nov. 15	AQ
NanoViricides: Fiscal Q1 Earnings Snapshot	Nov. 15	AQ
NanoViricides, Inc. Has Filed its Annual Report	23-10-17	AQ
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant	23-09-27	AQ
NanoViricides progressing well with new Covid study	23-08-31	AQ
The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides	23-08-22	AQ
SARS-CoV-2 Is Not Done Yet Ã¢€” Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19?	23-07-19	AQ
NanoViricides testing oral gummy and syrup Covid-19 treatment - Proactive Research Analyst	23-07-13	AQ
Company's Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides	23-07-12	AQ
Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials Ã¢€“ What Other Viruses Could This COVID Treatment Target?	23-07-11	AQ
NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment	23-07-06	AQ
NanoViricides take big step forward beginning trials on its antiviral drug NV-CoV-2	23-06-29	AQ
NanoViricides, Inc.	23-06-29	AQ
NANOVIRICIDES, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	23-05-25	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases NanoViricides, Inc.

Equities

NNVC

US6300873022

Press Releases

Filters